Background
Phosphatidylinositol-3-kinase (PI3K)/Akt pathway has been described to be critical in the survival of chronic lymphocytic leukemia (CLL) cells. In this article we have analyzed the effect of two selective chemical inhibitors of Akt (Akti-1/2 and A-443654) in the survival of CLL cells.
Design and Methods
We studied by cytometric analysis the cytotoxic effects of Akt inhibitors on peripheral B and T lymphocytes from patients with CLL and from healthy donors. We studied the changes induced by Akti-1/2 and A-443654 at mRNA level by performing reverse transcriptase multiplex ligation-dependent probe amplification. We also studied the changes induced by both Akt inhibitors in some BCL-2 protein family members on CLL cells by Western blot. Moreover, we analyzed the cytotoxic effect of Akt inhibitors in patient cells with deleted/mutated TP53.
Results
Both inhibitors induced apoptosis in CLL cells in a dose-dependent manner. Moreover, B cells from CLL samples were more sensitive to Akt inhibitors than T cells from CLL samples, and B or T cells from healthy donors. Survival factors for CLL cells, such as IL-4 and SDF-1a, were not able to block the apoptosis induced by both Akt inhibitors. Akti-1/2 did not induce any change in the mRNA expression profile of genes involved in apoptosis, while A-443654 induced some changes, including an increase in NOXA and PUMA mRNA levels, suggesting the existence of additional targets for A-443654. Both inhibitors induced an increase in PUMA and NOXA protein levels, and a decrease in MCL-1 protein level. Moreover, Akti-1/2 and A-443654 induced apoptosis irrespective of TP53 status.
Conclusions
These results demonstrate that Akt inhibitors induce apoptosis of CLL cells and might be a new therapeutic option for the treatment of CLL.
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Introduction
Phosphatidylinositol-3-kinase (PI3K) pathway has been described to be critical in the survival of chronic lymphocytic leukemia (CLL) cells.
1-11 PI3K phosphorylates the D-3 position of phosphatidylinositol, phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-diphosphate. The cellular levels of PI3K products are controlled by the balance between the PI3K activity and the phosphatase activity of PTEN (Phosphatase and Tensin homolog deleted on chromosome ten).
12
Interestingly, PTEN protein is reduced or not detected in 48% of CLL patients.
13
One of the most important targets of PI3K products is the serine-threonine kinase Akt, also known as protein kinase B (PKB).
14 Akt resides in the cytosol in a low-activity conformation, and it is activated through recruitment to cell membranes by PI3K lipid products and phosphorylation at Thr308 and Ser473. Once Akt is activated, it is able to promote cell survival, through phosphorylation and inactivation of key components in the apoptotic cascade. Akt substrates include the members of the Forkhead family of transcription factors 15 and glycogen synthase kinase-3 (GSK-3), 16 which are inhibited by Akt. Furthermore, GSK-3 inhibition induces the upregulation of the antiapoptotic protein MCL-1.(16) Activation of PI3K/Akt pathway in CLL cells induces the phosphorylation of the Forkhead family member FoxO3a and GSK-3, and an increase in MCL-1 protein, while inhibition of PI3K induces a loss of cell viability, dephosphorilation of FoxO3a and GSK-3, and a decrease in MCL-1 protein level.
3,4,11
Importantly, a stronger activation of Akt pathway has been related to a higher capacity for cell cycle progression in CLL cells from patients with progressive disease.
17
All together, these studies suggest that Akt plays a prominent role in CLL cells survival, however the effect of selective chemical Akt inhibitors on the survival of CLL cells has not been reported yet. A-443654 is a potent, ATP competitive and reversible inhibitor of Akt catalized phosphoryation activity. It is a pan Akt inhibitor and has equal potency against Akt1, Akt2 or Akt3.
18,19 It has been described that together with the decrease in phosphorylation of Akt targets, it is observed a concomitant increase in the phosphorylation of Ser473 and Thr308 Akt residues. This increase is PI3K dependent, as cell incubation with LY294002 blocks it. 20 Recently, it has been described that this inhibitor also inhibited other protein kinases with slightly lower potency, such as PKA, PRK2, MSK1 and DYRK1A. 21 They also reported that Akti-1/2, an ATP non-competitive Akt inhibitor, was a highly selective Akt inhibitor. It blocks Akt1 and Akt2 but not Akt3 activity, and the PH (pleckstrin homology) domain is required for the activity of this inhibitor.
22,23
In this paper, we have examined the effect of these two Akt inhibitors in CLL cells. We demonstrate that both Akti-1/2 and A-443654 induce apoptosis in CLL cells and modulate BCL-2 family proteins, and this occurs likely through distinct mechanisms. Our results suggest that Akt inhibitors may provide a novel therapeutic option for CLL patients.
Design and Methods
Patients with CLL, healthy donors and cell isolation Samples from patients with CLL (Table 1) 
Patients analysis
CD38 and ZAP-70 were determined by flow cytometry in fixed cells with conjugated antibodies (PE clon HB7, Becton Dickinson, Franklin Lakes, NJ, USA; and Alexa-Fluor 488, Caltag Laboratories, Burlingame, CA, USA, respectively). CD19 was determined by flow cytometry with a conjugated antibody (phycoerythrin (PE)-conjugated anti-CD19 Becton Dickinson).
Genomic alterations were detected by Fluorescence in situ hybridization (FISH). Fluorescent-labeled DNA probes were used in interphase cytogenetic analyses. Locus-specific probes (LSI P53/Spectrum-Orange, LSI ATM/SpectrumGreen, LSI 13S319/Spectrum-Orange, LSI 13q34/SpectrumAqua) were used to determine loss of these genetic regions within interphase nuclei. Trisomy 12 was detected in interphase nuclei using a chromosomal centromere enumeration probe (CEP) labeled with Spectrum-Green. These five probes are packaged together in a commercially available kit (Vysis Chronic Lymphocytic Leukaemia Multicolor Kit) and were used in accordance with the manufacturer's specifications. Cells were fixed with fresh fixative before placement onto slides. Probe mixture was applied directly to slides. These slides were denaturated at 74ºC for 2 min and incubated overnight at 37ºC. Slides were then washed with 0.4 x saline sodium citrate (SSC)-0.3% nonidet P-40 (NP-40) at 73±1ºC for 2 min and 2 x SSC-0.1% NP-40 at room temperature for 1 min. 4'6-diamidino-2-phenylindole (DAPI) II counterstain (10 ll) was applied to the target area. Slides were stored at 20ºC in the dark. Two hundred nuclei were analyzed per each probe, using a NIKON fluorescent microscope. Cut off levels used were 5% for CEP 12 and 7% for LSI probes. Karyotype analysis was performed in all samples.
Reagents
Akti-1/2 (previously known as Akt-I-1/2) was purchased from Calbiochem-Novabiochem (San Diego, CA, USA), A-443654 was kindly provided by Abbott (North Chicago, IL, USA), recombinant human IL-4 and stromal cell-derived factor-1α (SDF-1α) were purchased from Immunotools (Friesoythe, Germany), annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) were from Bender MedSystems (Vienna, Austria). Nutlin-3a was provided by Hoffmann-La Roche. Z-VAD.fmk was purchased from Bachem (Bubendorf, Switzerland). Ethanol and RNase A were from Sigma-Aldrich.
Cell culture
Lymphocytes were cultured immediately after thawing or isolation in RPMI 1640 culture medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, 100 U penicillin and 100 ng/mL streptomycin at 37°C in a humidified atmosphere containing 5% carbon dioxide. To avoid differences in cell viability due to the concentration, flow cytometry experiments were performed at a concentration of 1×10 6 cells/mL, whereas RT-MLPA and the experiments done to obtain cell extracts to perform Western blot were performed at a concentration of 2.5 to 3×10 6 cells/mL.
Analysis of apoptosis by flow cytometry
Apoptosis was assessed by exposure of phosphatidylserine and membrane integrity. This was determined by annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) double staining. Flow cytometric analysis was performed using FACSCalibur and CellQuest software (Becton Dickinson), as described previously.(24) Cell viability was measured as the percentage of annexin V and PI double-negative cells. Flow cytometry analysis of three representative samples is shown in Online Supplementary Figure 1A .
To analyze apoptosis in T cells and B cells from the samples, 5×10 5 cells were incubated for 24 hours with the indicated factors. Cells were then washed in annexin-binding buffer (ABB), and incubated in 50 µL annexin-binding buffer with allophycocyanin (APC)-conjugated anti-CD3 and phycoerythrin (PE)-conjugated anti-CD19 from Becton Dickinson, for 10 minutes in the dark. Cells were then diluted with annexin-binding buffer to a volume of 150 µL and incubated with 1 µL annexin V-FITC for 15 minutes in the dark. Cells were analyzed using the FACSCalibur and CellQuest software. Flow cytometry analysis of one CLL sample and one healthy donor are shown in Online Supplementary figure 1B.
Apoptosis in T cells and B cells was also assessed by subdiploid DNA analysis. Briefly, 1×10 6 cells were harvested, washed twice in phosphate-buffered saline containing 1% foetal bovine serum (PBS/1% FBS) and fixed in 70% ethanol. Cell were centrifuged, washed in PBS/1% FBS, and resuspended in 0.5 mL PBS/1% FBS, containing allophycocyanin (APC)-conjugated anti-CD3 or allophycocyanin (APC)-conjugated anti-CD19. Tubes were incubated for 20 minutes at room temperature in the dark. Then PI (50 mg/mL) and RNase A (100 mg/mL) were added and incubated 30 minutes at room temperature on the dark before flow cytometry analysis to identify the sub-G0 peak corresponding to apoptosis in CD3 + or CD19 + cells. Cells were analyzed using the FACSCalibur and CellQuest software.
Western blot analysis
Cells were lysed with Laemmli sample buffer, and Western blot analysis was performed as described previously. 2 We used antibodies against p53 (Ab-5, Neomarkers, Fremont, CA, USA), MCL-1 and Akt (Santa Cruz Biotechnology, Santa Cruz, CA, USA), BCL-2 (Dako, A/S, Glostrup, Denmark), PUMA and NOXA (Abcam, Cambridge, UK), P-Ser473-Akt, P-GSK-3a/b and P-FoxO1/FoxO3a (Cell Signaling Technologies, Beverly, MA, USA), and b-actin (SigmaAldrich). Antibody binding was detected using a secondary antibody conjugated to horseradish peroxidase and the enhanced chemiluminescence (ECL) detection system (Amersham, Buckinghamshire, UK).
RT-MLPA
RNA was analyzed by reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) using SALSA MLPA KIT R011 Apoptosis mRNA from MRC-Holland (Amsterdam, The Netherlands) for the simultaneous detection of 38 messenger RNA molecules. 25 In brief, RNA samples (200 ng total RNA) were first reverse transcribed using a genespecific probe mix. The resulting cDNA was annealed overnight at 60°C to the MLPA probe mix. Annealed oligonucleotides were ligated by adding Ligase-65 (MRC-Holland, Amsterdam) and incubated at 54°C for 15 minutes. Ligation products were amplified by PCR (35 cycles, 30 seconds at 95°C; 30 seconds at 60°C, and 1 minute at 72°C) with one unlabeled and one FAM labeled primer. The final PCR fragments amplified were separated by capillary electrophoresis on a 48-capillary ABI-Prism 3730 Genetic Analyzer (Applied Biosystems/Hitachi, Foster City, CA). Peak area and height were measured using GeneScan analysis software (Applied Biosystems). The sum of all peak data was set at 100% to normalize for fluctuations in total signal between samples, and individual peaks were calculated relative to the 100% value.
Statistical analysis
Results are shown as the mean ± standard error of the mean (SEM) of values obtained in independent experiments. The paired Student's t test was used to compare differences between paired samples. Data were analyzed using the SPSS 14.0 software package (Chicago, IL, USA). 
Results

Akti-1/2 and A-443654 inhibit Akt in CLL cells
To assess the effect of Akti-1/2 and A-443654 on Akt activity in CLL cells, we examined the phosphorylation status of Akt or Akt substrates which are used to assess the activation status of Akt. Akti-1/2 inhibited Ser473 phosphorylation in a dose-dependent manner ( Figure 1A, n=3) . As previously described in other cell types, 18, 20 A-443654 induced an increase in Ser473 phosphorylation. In order to confirm that A-443654 was inhibiting Akt, we analyzed the status of the Akt substrates GSK3a/b and FoxO1/FoxO3a. Both inhibitors reduced the phosphorylation of GSK3a/b and FoxO1/FoxO3a ( Figure 1B ), demonstrating that they inhibited Akt activity. Four representative patients of nine are shown.
Akt inhibitors induce apoptosis in CLL cells
To examine the ability of Akt inhibitors to induce apoptosis in CLL cells, we incubated CLL cells with a range of Akti-1/2 (0.5-20 mM) and A-443654 (0.1-1 mM) concentrations for 24 hours and we measured cell viability. Both inhibitors induced apoptosis in a dosedependent manner (Figure 2, A and B, n=15 ) and in a time-dependent manner (Online Supplementary figure 2) . The half-maximal effective concentration (EC50) was 9.85±0.67 mM for Akti-1/2 (n=20) ranging from 5 to 15, and 0.63±0.03 mM for A-443654 (n=26) ranging from 0.40 to 0.85. Similar results were obtained in purified CD19
+ CLL cells (Online Supplementary figure  3) . Akti-1/2 and A-443654 induced apoptosis in all the analyzed samples, independently of sex, ZAP70 status, CD38 status or genomic alterations (data not shown). Supplementary figure 4) . We confirmed this differential induction of apoptosis between CLL cells and normal lymphocytes by performing an analysis of the DNA content. We observed that CLL cells were more sensitive than T cells and normal B cells to Akt inhibitorsinduced increase in sub-G0 peak (Online Supplementary figure 5) . These results indicate that B cells from CLL samples are more sensitive than normal B and T cells to Akt inhibitors-induced apoptosis.
Differential effect of Akt inhibitors on B and T cells from CLL and healthy donors
Effect of survival factors in combination with Akt inhibitors
We studied the effect of two well-known survival factors in CLL cells, IL-4 (26) and SDF-1a, (27) in combination with Akt inhibitors. We used selected CLL samples where these factors induced a survival effect. Thus, we treated CLL cells with 10 ng/mL IL-4 ( Figure  3A , n = 10) or 50 ng/mL SDF-1a ( Figure 3B, n=7) and with or without 10 mM Akti-1/2 or 0.5 mM A-443654 during 48 hours, and then we measured cell viability. Neither IL-4 nor SDF-1a were able to inhibit the apoptosis induced by both Akt inhibitors. These results show that Akt inhibitors can induce apoptosis in CLL cells even in the presence of survival signals.
Characterization of Akt inhibitors-induced apoptosis in CLL
We investigated the effect of Akt inhibitors in the overall apoptosis mRNA expression profile by per- Supplementary figure 7) . Thus, A-443654-induced mRNA changes are likely independent of its activity inhibiting Akt. Then, we investigated the effect of Akt inhibitors on the expression of BCL-2 family proteins. Western blot analysis revealed an induction of the NOXA protein levels and a decrease in MCL-1 protein levels by Akti-1/2 and A-443654 in all the analyzed samples. PUMA protein levels were also increased in fifty per cent of the samples after Akt inhibitors treatment ( Figure 5A , three representative patients are shown, n = 10 for Akti-1/2 and n = 13 for A-443654). Furthermore, p53 protein was increased by A-443654 but not by Akti-1/2 in all the analyzed samples.
We further analyzed the apoptosis-related protein expression profile induced by Akti-1/2 and A-443654 at different times. We did not observed any change in MCL-1, NOXA and PUMA protein levels after 3 hours of Akt inhibitors treatment (data not shown). NOXA protein was increased by Akt inhibitors at 6 hours while PUMA protein levels were increased at 12 hours. Moreover, MCL-1 protein was decreased after incubation with A-443654 for 6 hours (Online Supplementary Western blot analysis revealed an increase in NOXA levels in the three samples with both inhibitors treatment, while PUMA levels increased in only one sample (patient 8) with 5 mM Akti-1/2 treatment. MCL-1 levels decreased with Akti-1/2 in patients 8 and 41, where Akti-1/2 induced apoptosis. In patient 40, MCL-1 levels increased with Akti-1/2 treatment, and the inhibitor did not induce apoptosis. A-443654 treatment induced MCL-1 levels decrease in the three samples ( Figure 6A ). As a control of TP53 status we used 5 mM Nutlin-3a, which has been described to induce apoptosis and p53 accumulation in wild-type TP53 cells but not in deleted/mutated TP53 cells.(28) Next, we examined the apoptosis mRNA expression profile by performing RT-MLPA. Incubation with 5 mM Akti-1/2 or 0.5 mM A-4436545 induced almost the same mRNA expression profile than in TP53 wild type CLL cells, except that PUMA mRNA levels did not increase after A-443654 treatment ( Figure 6B ).
Discussion
In this paper we have tested the effect of two Akt inhibitors on the viability of CLL cells. Both Akt inhibitors induce apoptosis in primary CLL cells. These results are in agreement with the recent report describing that introduction of constitutively active myr.Akt increases the viability of CLL cells.
31
The mechanism of action of both Akt inhibitors is somewhat different (Online Supplementary figure 9) . Surprisingly, Akti-1/2 inhibits Akt but does not induce changes in the RT-MLPA profile. Akt modulates the transcriptional activity of at least one transcription factor, FoxO3a, 15 which would induce changes in the mRNA levels of its transcriptional targets BIM 32 and PUMA.
33 However, RT-MLPA experiments suggest that dephosphorylation of FoxO3a induced by Akti-1/2 is not sufficient to induce the transcription of BIM and PUMA in CLL cells. As A-443654 is a less specific Akt-inhibitor, 21 the simplest model would be to consider that inhibition of Akt (common to both inhibitors) does not induce changes in the RT-MLPA profile, and that A-443654 has additional targets to explain its effects on the expression of genes.
Thus, A-443654 induces an increase in the levels of p53 protein and the induction of PUMA mRNA, a transcriptional target of TP53 in CLL. 28, 34 In agreement with this data, the induction of PUMA mRNA by A-443654 was decreased in CLL cells with deleted/mutated TP53. Interestingly, Akti-1/2 induced PUMA and NOXA proteins without affecting PUMA and NOXA mRNA. The mechanism for this effect is unknown and could be explained by increased translation or decreased proteolysis of these proteins.
A common event of both Akt inhibitors is the modulation of NOXA/MCL-1 balance. It has been reported that in primary CLL cells, the majority of NOXA protein is associated with MCL-1.
35
Thus, Akti-1/2 and A-443654 treatment induced an increase in NOXA protein levels and a downregulation of MCL-1 protein levels, a critical survival protein in CLL cells. Furthermore, inhibition of caspases prevents the downregulation of MCL-1 induced by Akti-1/2, suggesting that MCL-1 cleavage would participate in an amplification loop that would increase cytochrome c release and apoptosis in CLL cells, as described for PKC inhibitors. 36 In agreement with our results, introduction of constitutively active myr.Akt increases MCL-1 protein and inhibition of MCL-1 by siRNA treatment induces apoptosis in CLL. 31 The mechanism of regulation of MCL-1 protein by Akt in CLL cells is unknown. The Akt substrate GSK-3 has been reported to induce the destabilization of MCL-1 protein. 16 However, inhibition of GSK-3 does not inhibit the apoptotic effect of PI3K inhibitors.
7 As GSK-3 is inhibited by PKC, 37 perhaps the overexpression of active PKC-βII 38 blocks this pathway in CLL cells. Our results indicate that B cells from CLL samples were more sensitive to Akt inhibitors than T cells from CLL samples, and B or T cells from healthy donors. Chemotherapeutic drugs, including fludarabine, chlorambucil, and doxorubicin induce apoptosis equally in both B and T cells, leading to immunosupression.
39,40
Thus, the differential effect of Akti-1/2 and A-443654 in B and T lymphocytes is of interest. In conclusion, the results presented here suggest that clinically suitable small-molecule inhibitors of Akt alone or in combination with chemotherapeutic drugs might be a new therapeutic option for the treatment of CLL. 
